APO RESEARCH · REPORT
Hydroxycarbamide
Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.
Product & engineering
Understand the product.
Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.
Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.
Selected research
Industry Research
Hydroxycarbamide Industry Research Report 2026
Market perspective
Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it decreases the number of attacks. It is taken by mouth.
Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, shortness of breath, and headaches. There is also concern that it increases the risk of later cancers. Use during pregnancy is typically harmful to the baby. Hydroxycarbamide is in the antineoplastic family of medications. It is believed to work by blocking the making of DNA.
Global Hydroxycarbamide key players include Qilu Pharmaceutical, Beijing Jialin Pharma, Taj Pharma, etc. Global top three manufacturers hold a share over 35%.
Read the full market overview
Asia-Pacific is the largest market, with a share nearly 60%, followed by Europe, and North America, both have a share about 40 percent.
In terms of product, Capsule is the largest segment, with a share over 60%. And in terms of application, the largest application is Sickle Cell Disease, followed by Cancer, etc.
Report Scope
This report quantifies the global Hydroxycarbamide market in terms of revenue (US$ million) and, where applicable, sales volume (M Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Hydroxycarbamide Market by Company
Bristol Myers Squibb
Taj Pharma
Beijing Jialin Pharma
Qilu Pharmaceutical
Teva Pharma
Cipla
Zydus Cadila
United Biotech
Par Pharma
Khandelwal Laboratories
Alkem (Cytomed)
Samarth Pharma
VHB Life Sciences
Hydroxycarbamide Segment by Type
Capsule
Tablet
Hydroxycarbamide Segment by Application
Sickle Cell Disease
Cancer
Others
Hydroxycarbamide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hydroxycarbamide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hydroxycarbamide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hydroxycarbamide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Hydroxycarbamide manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Hydroxycarbamide by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Hydroxycarbamide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Capsule
- Tablet
Applications
- Sickle Cell Disease
- Cancer
- Others
Companies covered
- Bristol Myers Squibb
- Taj Pharma
- Beijing Jialin Pharma
- Qilu Pharmaceutical
- Teva Pharma
- Cipla
- Zydus Cadila
- United Biotech
- Par Pharma
- Khandelwal Laboratories
- Alkem (Cytomed)
- Samarth Pharma
- VHB Life Sciences
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Hydroxycarbamide Market Size (2021-2032)
- 2.2.2 Global Hydroxycarbamide Sales (2021-2032)
- 2.2.3 Global Hydroxycarbamide Market Average Price (2021-2032)
- 2.3 Hydroxycarbamide by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Capsule
- 2.3.3 Tablet
- 2.4 Hydroxycarbamide by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Sickle Cell Disease
- 2.4.3 Cancer
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Hydroxycarbamide Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Hydroxycarbamide Sales (M Units) of Manufacturers (2021-2026)
- 3.3 Global Hydroxycarbamide Revenue of Manufacturers (2021-2026)
- 3.4 Global Hydroxycarbamide Average Price by Manufacturers (2021-2026)
- 3.5 Global Hydroxycarbamide Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Hydroxycarbamide, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Hydroxycarbamide, Product Type & Application
- 3.8 Global Manufacturers of Hydroxycarbamide, Established Date
- 3.9 Global Hydroxycarbamide Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bristol Myers Squibb
- 4.1.1 Bristol Myers Squibb Company Information
- 4.1.2 Bristol Myers Squibb Business Overview
- 4.1.3 Bristol Myers Squibb Hydroxycarbamide Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bristol Myers Squibb Hydroxycarbamide Product Portfolio
- 4.1.5 Bristol Myers Squibb Recent Developments
- 4.2 Taj Pharma
- 4.2.1 Taj Pharma Company Information
- 4.2.2 Taj Pharma Business Overview
- 4.2.3 Taj Pharma Hydroxycarbamide Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Taj Pharma Hydroxycarbamide Product Portfolio
- 4.2.5 Taj Pharma Recent Developments
- 4.3 Beijing Jialin Pharma
- 4.3.1 Beijing Jialin Pharma Company Information
- 4.3.2 Beijing Jialin Pharma Business Overview
- 4.3.3 Beijing Jialin Pharma Hydroxycarbamide Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Beijing Jialin Pharma Hydroxycarbamide Product Portfolio
- 4.3.5 Beijing Jialin Pharma Recent Developments
- 4.4 Qilu Pharmaceutical
- 4.4.1 Qilu Pharmaceutical Company Information
- 4.4.2 Qilu Pharmaceutical Business Overview
- 4.4.3 Qilu Pharmaceutical Hydroxycarbamide Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Qilu Pharmaceutical Hydroxycarbamide Product Portfolio
- 4.4.5 Qilu Pharmaceutical Recent Developments
- 4.5 Teva Pharma
- 4.5.1 Teva Pharma Company Information
- 4.5.2 Teva Pharma Business Overview
- 4.5.3 Teva Pharma Hydroxycarbamide Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Teva Pharma Hydroxycarbamide Product Portfolio
- 4.5.5 Teva Pharma Recent Developments
- 4.6 Cipla
- 4.6.1 Cipla Company Information
- 4.6.2 Cipla Business Overview
- 4.6.3 Cipla Hydroxycarbamide Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Cipla Hydroxycarbamide Product Portfolio
- 4.6.5 Cipla Recent Developments
- 4.7 Zydus Cadila
- 4.7.1 Zydus Cadila Company Information
- 4.7.2 Zydus Cadila Business Overview
- 4.7.3 Zydus Cadila Hydroxycarbamide Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Zydus Cadila Hydroxycarbamide Product Portfolio
- 4.7.5 Zydus Cadila Recent Developments
- 4.8 United Biotech
- 4.8.1 United Biotech Company Information
- 4.8.2 United Biotech Business Overview
- 4.8.3 United Biotech Hydroxycarbamide Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 United Biotech Hydroxycarbamide Product Portfolio
- 4.8.5 United Biotech Recent Developments
- 4.9 Par Pharma
- 4.9.1 Par Pharma Company Information
- 4.9.2 Par Pharma Business Overview
- 4.9.3 Par Pharma Hydroxycarbamide Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Par Pharma Hydroxycarbamide Product Portfolio
- 4.9.5 Par Pharma Recent Developments
- 4.10 Khandelwal Laboratories
- 4.10.1 Khandelwal Laboratories Company Information
- 4.10.2 Khandelwal Laboratories Business Overview
- 4.10.3 Khandelwal Laboratories Hydroxycarbamide Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Khandelwal Laboratories Hydroxycarbamide Product Portfolio
- 4.10.5 Khandelwal Laboratories Recent Developments
- 4.11 Alkem (Cytomed)
- 4.11.1 Alkem (Cytomed) Company Information
- 4.11.2 Alkem (Cytomed) Business Overview
- 4.11.3 Alkem (Cytomed) Hydroxycarbamide Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Alkem (Cytomed) Hydroxycarbamide Product Portfolio
- 4.11.5 Alkem (Cytomed) Recent Developments
- 4.12 Samarth Pharma
- 4.12.1 Samarth Pharma Company Information
- 4.12.2 Samarth Pharma Business Overview
- 4.12.3 Samarth Pharma Hydroxycarbamide Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Samarth Pharma Hydroxycarbamide Product Portfolio
- 4.12.5 Samarth Pharma Recent Developments
- 4.13 VHB Life Sciences
- 4.13.1 VHB Life Sciences Company Information
- 4.13.2 VHB Life Sciences Business Overview
- 4.13.3 VHB Life Sciences Hydroxycarbamide Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 VHB Life Sciences Hydroxycarbamide Product Portfolio
- 4.13.5 VHB Life Sciences Recent Developments
5 Global Hydroxycarbamide Market Scenario by Region
- 5.1 Global Hydroxycarbamide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Hydroxycarbamide Sales by Region: 2021-2032
- 5.2.1 Global Hydroxycarbamide Sales by Region: 2021-2026
- 5.2.2 Global Hydroxycarbamide Sales by Region: 2027-2032
- 5.3 Global Hydroxycarbamide Revenue by Region: 2021-2032
- 5.3.1 Global Hydroxycarbamide Revenue by Region: 2021-2026
- 5.3.2 Global Hydroxycarbamide Revenue by Region: 2027-2032
- 5.4 North America Hydroxycarbamide Market Facts & Figures by Country
- 5.4.1 North America Hydroxycarbamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Hydroxycarbamide Sales by Country (2021-2032)
- 5.4.3 North America Hydroxycarbamide Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Hydroxycarbamide Market Facts & Figures by Country
- 5.5.1 Europe Hydroxycarbamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Hydroxycarbamide Sales by Country (2021-2032)
- 5.5.3 Europe Hydroxycarbamide Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Hydroxycarbamide Market Facts & Figures by Country
- 5.6.1 Asia Pacific Hydroxycarbamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Hydroxycarbamide Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Hydroxycarbamide Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Hydroxycarbamide Market Facts & Figures by Country
- 5.7.1 South America Hydroxycarbamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Hydroxycarbamide Sales by Country (2021-2032)
- 5.7.3 South America Hydroxycarbamide Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Hydroxycarbamide Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Hydroxycarbamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Hydroxycarbamide Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Hydroxycarbamide Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Hydroxycarbamide Sales by Type (2021-2032)
- 6.1.1 Global Hydroxycarbamide Sales by Type (2021-2032) & (M Units)
- 6.1.2 Global Hydroxycarbamide Sales Market Share by Type (2021-2032)
- 6.2 Global Hydroxycarbamide Revenue by Type (2021-2032)
- 6.2.1 Global Hydroxycarbamide Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Hydroxycarbamide Revenue Market Share by Type (2021-2032)
- 6.3 Global Hydroxycarbamide Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Hydroxycarbamide Sales by Application (2021-2032)
- 7.1.1 Global Hydroxycarbamide Sales by Application (2021-2032) & (M Units)
- 7.1.2 Global Hydroxycarbamide Sales Market Share by Application (2021-2032)
- 7.2 Global Hydroxycarbamide Revenue by Application (2021-2032)
- 7.2.1 Global Hydroxycarbamide Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Hydroxycarbamide Revenue Market Share by Application (2021-2032)
- 7.3 Global Hydroxycarbamide Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Hydroxycarbamide Value Chain Analysis
- 8.1.1 Hydroxycarbamide Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Hydroxycarbamide Production Mode & Process
- 8.2 Hydroxycarbamide Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Hydroxycarbamide Distributors
- 8.2.3 Hydroxycarbamide Customers
9 Global Hydroxycarbamide Analyzing Market Dynamics
- 9.1 Hydroxycarbamide Industry Trends
- 9.2 Hydroxycarbamide Industry Drivers
- 9.3 Hydroxycarbamide Industry Opportunities and Challenges
- 9.4 Hydroxycarbamide Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst